Duramycin is a heavily post-translationally modified peptide that binds phosphatidylethanolamine. It has been investigated as an antibiotic, an inhibitor of viral entry, a therapeutic for cystic fibrosis, and a tumor and vasculature imaging agent. Duramycin contains a β -hydroxylated Asp (Hya) and four macrocycles, including an essential lysinoalanine (Lal) cross-link. The mechanism of Lal formation is not known. Here we show that Lal is installed stereospecifically by DurN via addition of Lys19 to a dehydroalanine. The structure of DurN reveals an unusual dimer with a new fold. Surprisingly, in the structure of duramycin bound to DurN, no residues of the enzyme are near the Lal cross-link. Instead, Hya15 of the substrate makes interactions with Lal, suggesting it acts as a base to deprotonate Lys19 during catalysis. Biochemical data suggest that DurN preorganizes the reactive conformation of the substrate, such that the Hya15 of the substrate can serve as the catalytic base for Lal formation.
D uramycin and closely related compounds are ribosomally synthesized and post-translationally modified peptides (RiPPs) produced by various actinomycetes [1] [2] [3] [4] [5] and marine symbionts 6 . Duramycin binds phosphatidylethanolamine (PE), a major structural phospholipid in mammalian and microbial cell membranes 7, 8 . Duramycin contains 19 amino acids and 5 post-translational modifications (PTMs): one lanthionine (Lan), two methyllanthionines (MeLan), an erythro-3-hydroxy-l-aspartic acid (Hya) resulting from hydroxylation of Asp15, and one (2S,9S)-Lal (Fig. 1a) . The carboxylate and hydroxyl groups of Hya15 make key interactions with the ethanolamine head group of PE, providing nanomolar affinity and high specificity 8, 9 . As such, duramycin has been investigated as an antibiotic [1] [2] [3] , an inhibitor of viral entry 10 , a therapeutic for cystic fibrosis 11 , and a tumor and vasculature imaging agent 12, 13 . Recently, divamide A, a close homolog of duramycin discovered from the symbiotic microbiome of small marine animals, was reported to display potent anti-HIV activity 6 .
Previous studies have identified the biosynthetic genes (dur) encoding the enzymes that introduce these PTMs in Streptomyces cinnamoneus ATCC12686 (ref. 14 ) . The precursor peptide DurA is synthesized with an N-terminal leader peptide (LP) that is removed after maturation of a C-terminal core peptide (CP) (Fig. 1a ). Serine and threonine residues in the CP region of DurA are dehydrated by DurM to form dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues. Subsequently, DurM catalyzes addition of cysteine thiols onto the β -carbon of Dha or Dhb to produce Lan or MeLan, respectively (Fig. 1a ). The final two PTMs are hydroxylation of Asp15 by DurX to generate Hya15 and formation of (2S,9S)-Lal putatively by DurN-catalyzed addition of Lys19 to Dha6 (Fig. 1a) 14 .
A previous study demonstrated that duramycin lacking Lal does not have antimicrobial activity 14 , indicating that the Lal linkage is critical for setting up the PE binding pocket. DurN and its orthologs have no sequence homology with any characterized proteins, their mechanism of Lal formation is not known, and previous attempts to reconstitute activity of orthologs in vitro were unsuccessful 4, 15 . Instead, prior studies have resorted to nonenzymatic base-catalyzed formation of Lal 6, 15 .
In this study, we demonstrate DurN activity in vitro and present the co-crystal structures of the protein with a substrate analog and product. We compared Lal formation under enzymatic and nonenzymatic conditions, indicating that only DurN catalyzes diastereoselective Lal formation. Our data suggest that DurN promotes Lal formation via an unusual substrate-assisted mechanism.
Results
In vitro DurN activity. In previous studies, the DurN orthologs CinN and MatN were expressed as His 6 -tagged proteins and were devoid of enzymatic activity. In this work, DurN was expressed in Escherichia coli as an N-terminal fusion with maltose-binding protein (MBP-DurN; Supplementary Fig. 1 ). To prepare its putative substrate, the precursor peptide DurA was converted in E. coli to an intermediate 1 containing Lan, MeLan, and Hya residues but lacking Lal by co-expression with DurM and DurX 14 . We also generated the desired product 2 by co-expression of DurA with DurM, DurX, and DurN in E. coli. To test the requirement of the leader peptide, the majority of the leader peptide was removed from purified peptide 1 by endoproteinase Glu-C, yielding compound 3 , with three N-terminal residues (AlaPheAla) originating from the leader peptide ( Fig. 1b) . Similarly, treatment of peptide 2 with Glu-C resulted in compound 4 , containing all the PTMs found in duramycin ( Fig. 1b) 14 . Because addition of Lys19 to Dha6 to form the desired Lal does not lead to a change in mass or to a change in retention time, we adopted an indirect assay to follow Lal formation. Peptides 1 and 3 contain an electrophilic Dha, whereas peptides 2 and 4 do not. Hence, dithiothreitol (DTT) was used to monitor unreacted peptide by liquid chromatography-mass spectrometry (LC-MS) ( Supplementary Fig. 2 ).
We first reacted 1 with MBP-DurN in vitro and then treated it with DTT; a DTT adduct was not observed, suggesting that DurN performed the desired activity. We then reacted the truncated peptide 3 with MBP-DurN, and again the product was not reactive toward DTT, whereas adduct 5 was formed nearly quantitatively in control assays (Fig. 1c) . The products were also analyzed by LC-MS/ MS, demonstrating that the y1 ion is observed for 3 and 5 , but not for the product of the MBP-DurN reaction because of the formation of the Lal ring ( Fig. 1d ; Supplementary Fig. 2b ). Finally, as discussed in more detail in a later section, we hydrolyzed the product peptide of the MBP-DurN reaction and observed the presence of Lal by gas chromatography coupled to mass spectrometry (GC-MS). Thus, MBP-DurN catalyzes in vitro Lal formation in peptide 3 to generate product 4 , thereby also demonstrating that the leader peptide is not required for its activity.
The structure of DurN with a substrate analog. We removed the MBP tag from MBP-DurN (see Methods) and obtained crystal structures of DurN in complex with a substrate analog and in complex with duramycin. We generated an unreactive variant of 3 in which Dha6 (originating from Ser6 in DurA) was mutated to Ala (6 , Supplementary Fig. 3a ). The structure of DurN with 6 was solved to 1.90 Å resolution by single-wavelength anomalous dispersion (SAD) methods using an iodide-soaked crystal. DurN also crystallized in the apo form and the structure was solved to 2.15 Å by molecular replacement using the SAD-derived coordinates ( Fig. 2a ). The overall structure of DurN consists of an interlaced homodimer in which the α -helix 1 of each monomer is engaged with residues from α -helices 2-6 in the adjacent monomer. The α -helices are followed by a single β -strand that forms an intermolecular, antiparallel interaction with its neighboring β -strand ( Fig. 2a, b) . A query against the PDB 16 using the DALI server 17 shows that DurN does not confidently resemble any known domain, indicating that DurN contains a new protein fold and dimerization mode.
The homodimer contains two structural ions that are related by the pseudo two-fold symmetry axis of the DurN homodimer. Our data are consistent with the bound metal ions being potassium ( Supplementary Figs 4 and 5 ). DurN coordinates potassium at both sites via an octahedral array of oxygen ligands derived from amides in the backbone ( Supplementary Fig. 4d ). In addition to potassium, we also considered the possibility that magnesium ions are bound at the ion-binding sites and carried out equivalent rounds of refinement in REFMAC5 (ref. 18 ) after modeling either potassium or magnesium ions independently. Whereas no positive signal was observed in the difference Fourier map (F o -F c ) at 3σ for the corresponding potassium-bound model, a positive difference signal was observed for the magnesium-bound model ( Supplementary Fig. 4c ). Additional support for structural potassium ions was gathered by performing differential scanning fluorimetry (DSF), whereby DurN melting curves were obtained in the presence of various concentrations of potassium or magnesium ions. Whereas potassium ions conferred an increase in thermal stability of DurN as a function of ion concentration, magnesium ions had no effect on DurN thermal stability ( Supplementary Fig. 4a,b ). Molecular dynamics (MD) simulations also favor a structural potassium ion over magnesium ( Supplementary Fig. 5 ), and we needed potassium in our assays for enzymatic activity and to prevent precipitation.
Analysis of simulated annealing difference Fourier maps (F o -F c ) of the apo structure and the structure with the bound substrate analog revealed electron density for 6 from Gln3 to Gly16 (Fig. 2c) , with the reactive Lys19 invisible owing to disorder. Only one of the two symmetric binding sites of the homodimer is occupied by ligand because of occlusion of the other site by residues from the N terminus of a different protomer. Recognition of the ligand is mediated by residues from α -helix 1 of one polypeptide and α -helices 4-6 of Supplementary Fig. 2 ). Expected and observed masses are listed in Supplementary  Table 2 . Experiment was performed independently three times with similar results. d, LC-MS/MS analysis of the products in c. Because of the extensive cross-linking, the only fragments observed in addition to the y1 ion are likely an a2 ion at m/z 191 and a phenyl fragment at m/z 120.
the second monomer. Surprisingly, the ligand bound to the periphery of DurN and Ala6 (corresponding to the Dha6 involved in Lal formation) is far removed from any residues of the enzyme (Fig. 2c ).
The structure of DurN with duramycin. The observed binding pose of 6 does not suggest an obvious mechanism of catalysis. We therefore determined the 1.66-Å resolution structure of DurN bound to duramycin. This structure revealed additional electron density in both binding sites of the DurN dimer, enabling modeling of the entire duramycin molecule including the Lal linkage ( Fig. 2d,e ). Globally, the two ligand-bound structures are highly similar, with an r.m.s. deviation of 0.45 Å over 1,400 atoms (including ligands) ( Fig. 2f ). The duramycin-bound structure reaffirms that DurN does not provide any residues that could catalyze the Michael-type addition and suggests that DurN may mediate Lal formation by serving as a molecular scaffold to bring Dha6 and Lys19 in close proximity. Notably, a bidentate hydrogen bond is observed between the guanidine of Arg17, the Hya15 hydroxyl group, and an amide backbone oxygen of residue 14 (formerly Cys14) of duramycin ( Fig. 2g ). The Gln20 and Gln89 side chains of DurN further extend the hydrogen bond network, and an electrostatic interaction is also observed between the carboxylate of Hya15 and Lys66 (Fig. 2g ). These interactions position one of the carboxylate oxygens of Hya15 at 3.3 Å from the Lal secondary amine nitrogen. Thus, it appears that DurN holds the Hya15 carboxylate of the substrate in a conformation that is poised to activate Lys19 (Fig. 3 ). The other Hya15 carboxylate oxygen is 4.1 Å from the α -carbon of Ala6. This suggests that it would shield the Si face of the reactive Dha6, thus promoting protonation by solvent of the enolate formed upon the addition of Lys19 from the more accessible Re face, resulting in the correct (2S,9S)-Lal diastereomer (Fig. 3 ). The structures do not provide any evidence for activation of the carbonyl oxygen of Dha6. In fact, the Ψ angle in Ala6 in duramycin is close to zero, very likely because of electrostatic repulsion between the carboxylate of Hya15 and the amide carbonyl of Ala6, which is directed toward the solvent. This strongly suggests that the reacting Dha6 is fixed in an s-cis conformation before cyclization, which has been found to be the more reactive form in other Michael-type additions occurring in lanthipeptide biosynthesis 19 .
Substrate-assisted Lal formation. The conformation of duramycin in the co-crystal structure is more constrained than the solution structure of its close analog cinnamycin bound to lysophosphatidylethanolamine (PDB 2DDE) 9 . Indeed, MD simulations demonstrate that the conformation of duramycin relaxes upon removal of DurN ( Supplementary Fig. 6 ). Notably, in the absence of DurN, Hya15 moves away from the Si face of Dha6. Given the apparent importance of the hydroxyl group of Hya15 for positioning its carboxylate, we also performed MD calculations on the complex in which this functionality was removed (i.e., Hya15 replaced by Asp). In the absence of the β -hydroxyl group, the carboxylate reorients to interact with Arg17 and Lys66, and thus the MD simulations predict it would no longer be available to act as a base ( Fig. 4 ).
To probe their roles, MBP-DurN variants of conserved residues ( Supplementary Fig. 7 ) were constructed and their activities determined with substrate 3 . Ala substitutions at positions involved in substrate binding (Arg17, Gln20, Gln89, and Lys66) resulted in inactive proteins, and the same outcome was observed for Arg18, Trp68, and Glu106 that are at the dimerization interface ( Supplementary Figs. 8 and 9 ). To investigate the effect on affinity upon mutation of substrate-binding residues, fluorescently labeled duramycin (Dur-FL, 7; Supplementary Fig. 3 ) was used for fluorescence polarization (FP) studies. Dur-FL bound to MBP-DurN with a K d of 417 ± 6 nM ( Supplementary Fig. 10a ). Unlabeled duramycin and substrate 3 were then used in competition FP experiments, providing inhibition constants (K i ) of 2.72 ± 0.01 μ M and 16.8 ± 0.5 μ M, respectively ( Supplementary Fig. 10b ). MBP-tagged DurN variants R17A, Q20A, and Q89A did not bind Dur-FL, whereas R17K bound very weakly and K66A provided a K i of 7.43 ± 0.08 μ M ( Supplementary Fig. 10b ). Collectively, the mutational data suggest that the binding modes observed in the co-crystal structures are functionally important because variants of residues that engage the substrate in the crystal are compromised with regards to both catalysis and substrate binding.
We also tested variants of substrate 3 . To maintain the hydroxyl group of Hya but not its carboxylate, a variant of 3 containing Ser in place of Hya15 (8 , Supplementary Fig. 3c ) was prepared in a similar fashion to 3 except for using DurA-D15S as a precursor peptide. Peptide 8 was a poor substrate for MBP-DurN ( Supplementary  Fig. 11 ), even though competition FP experiments show that this variant peptide inhibits Dur-FL binding with a K i of 10.2 ± 0.3 μ M ( Supplementary Fig. 10b ). Another variant of 3 , with Asp in place of Hya15 (9 ), was prepared by removing DurX from the E. coli coexpression system ( Supplementary Fig. 3f ). This variant was not processed by MBP-DurN in vitro ( Supplementary Fig. 11 ), in agreement with the predictions of the MD simulations described above. These data suggest that both functional groups on the Hya15 side chain (i.e., β -hydroxyl and γ -carboxylate) must be present for substrate to be processed by DurN.
Stereochemistry of enzymatic and non-enzymatic reactions.
The observation that 9 was not a substrate for DurN in vitro was surprising, because several studies have shown that deoxyduramycin/deoxycinnamycin can be obtained by co-expression of DurA/ CinA with DurM/CinM and DurN/CinN 20,21 . Thus, it appears that in bacteria, the absence of the hydroxyl group on Asp15 does not prevent Lal formation. To further investigate this apparent contradiction, we obtained deoxyduramycin (10 ) by co-expressing DurA with DurM and DurN in E. coli ( Supplementary Fig. 3g ). The product was treated with Glu-C to remove most of the leader peptide, and the three residues remaining from the leader peptide were removed using aminopeptidase. To probe whether duramycin and deoxyduramycin contained Lal, each peptide was hydrolyzed under acidic conditions to their constituent amino acids, which were derivatized as described previously (see Methods) 15 . GC-MS analysis indicated that authentic duramycin isolated from the producer organism predominantly contained the natural ll-Lal isomer (Fig. 5a ), as well as a small amount of epimer likely formed during acid hydrolysis 6, 15 . However, deoxyduramycin formed in E. coli contained about equal amounts of two diastereomers. Peptide 3 was then exposed to alkaline conditions that were previously used to form Lal nonenzymatically but for which the stereochemistry was not determined 15 . After removal of the leader peptide from the product peptide (11 ) , hydrolysis and analysis by GC-MS, two diastereomers of Lal were detected in roughly equal amounts, which was also observed when using a commercial mixture of (2R,9S)-Lal and (2S,9S)-Lal standards (Fig. 5a ). In contrast, product 4 obtained in vitro from DurN-catalyzed Lal formation again consisted predominantly of the (2S,9S)-Lal isomer. Collectively, these findings therefore suggest that Lal formation in E. coli when DurN is absent is nonstereoselective and may be nonenzymatic.
To explore the ramifications of the stereochemical information, we determined the antimicrobial activity of authentic duramycin, DurN-generated duramycin, and chemically generated duramycin using an agar diffusion assay against Bacillus subtilis ATCC 6633. These compounds all contain the Hya15 and should differ only in the Lal. As expected based on the stereochemical analysis ( Fig. 5a ), the product of DurN catalysis showed a zone of growth inhibition similar to that of authentic duramycin, whereas nonenzymatically produced 11 showed a zone of inhibition roughly half the size (Fig. 5b ).
Discussion
In this study, we provide the first in vitro demonstration that DurN catalyzes Lal formation, a step that had been recalcitrant in previous studies 6, 15 . By comparing enzymatic and nonenzymatic Lal generation, our data suggest that DurN greatly facilitates the reaction and controls its stereoselectivity. Furthermore, our data shows that the enzyme does not require the leader peptide for catalysis. DurN has a unique fold and dimeric architecture, and in co-crystal structures, the Lal is entirely solvent exposed and the Hya15 of the substrate is positioned to potentially act as a base during catalysis to deprotonate Lys19 to initiate the Michael-type addition. Additionally, Hya15 appears to shield the Si face of the enolate intermediate such that protonation will only occur from the Re face, resulting in the correct (2S,9S)-Lal product. Mutational studies show that substrates that lack either the hydroxyl or carboxylate groups of Hya15 are not processed by DurN despite maintaining binding affinity, suggesting that both of these groups on the substrate are indispensable for catalysis. Merging the biochemical findings with structural and computational insights points to a mechanism whereby the substrate employs its own Hya15 as a catalytic base to facilitate a Michael addition and stereo selective enolate protonation, resulting in Lal formation between Lys19 and Dha6.
The biosynthetic gene clusters of lysinoalanine-containing natural products such as duramycin and cinnamycin are very similar ( Supplementary Fig. 12a ) and all encode a DurN-like protein. This relatively small protein family is comprised of similar proteins, as shown by a tight sequence similarity network (SSN) of members identified by a BLAST search with DurN as query ( Supplementary  Fig. 12b) 22 . All identified homologs belong to duramycin-like lanthipeptide biosynthesis clusters that contain a type II lanthionine synthetase-like protein, a duramycin-like LanA precursor peptide, and a DurX-like protein. The natural products for some of these clusters have been characterized, and some of the LanN proteins (CinN, MarN) have been demonstrated to be important for Lal installation in vivo 4, 6, 14, 15, 23 . Because all of the LanA precursor peptides have a conserved Asp and a Lys close to the C terminus, it is likely that the Supplementary Fig. 11 ). 1, 2, 3, 4, 6, 8, 9 , and deoxyduramycin. E. coli BL21(DE3) cells were transformed with pRSFDuet-1/ His 6 -DurA/DurM and pACYCDuet-1/DurX to prepare compound 1 or with pRSFDuet-1/His 6 -DurA/DurM and pACYCDuet-1/DurN/DurX to prepare compound 2 . Treatment with endoproteinase Glu-C generated peptide 3 (from 1 ) and 4 (from 2 ). Cells were transformed with pRSFDuet-1/His6-DurA-Dha6Ala/ DurM and pACYCDuet-1/DurX to prepare 6 , with pRSFDuet-1/His 6 -DurA-Asp15Ser/DurM and pACYCDuet-1/DurX to prepare 8 , or with pRSFDuet-1/His 6 -DurA/DurM to prepare 9 . Transformants were plated on a LB agar plate containing 50 mg/L kanamycin and 50 mg/L chloramphenicol. E. coli BL21 (DE3) cells were transformed with pRSFDuet-1/His 6 -DurA/DurM, pMAL-DurN to prepare deoxyduramycin and the transformants were plated on a LB agar plate containing 50 mg/L kanamycin and 50 mg/mL ampicillin. The following procedures are the same for all preparations. A single colony was picked and grown in 5 mL of LB at 37 °C for 12 h containing antibiotics as described above, and the resulting culture was used to inoculate 1 L of LB containing the same antibiotics. When the OD 600 reached 0.75, the cultures were cooled on ice for 30 min, and then IPTG was added to 1.0 mM. The cells were cultured at 18 °C for another 18 h before harvesting by centrifugation at 8,000 × g for 10 min. Cell pellets were resuspended at 22-25 °C in LanA buffer 1 (6 M guanidine hydrochloride, 500 mM NaCl, 0.5 mM imidazole, 20 mM NaH 2 PO 4 , pH 7.5 at 25 °C) followed by sonication. The lysates were centrifuged at 18,000 × g for 30 min, and supernatants were passed through 0.45-µ m syringe filters. His-tagged modified peptides were purified by immobilized metal affinity chromatography (IMAC) loaded with nickel as previously described 14 . The fractions with the desired peptide were desalted by preparative RP-HPLC using an Agilent Bond Elut C18 column (3 mL). The desalted peptides were lyophilized, dissolved in 50 mM Tris pH 7.5 buffer, and digested by endoproteinase Glu-C at 20:1 (w/w). The digested reaction mixtures were purified by reversed-phase prep-HPLC (see 'General methods').
Production and purification of compounds
To prepare deoxyduramycin, the peptide was digested with aminopeptidase (0.1 U per µ g of peptide) at pH 8.5 at 22-25 °C overnight and purified by analytical HPLC ('General methods').
Dithiothreitol (DTT) assay to detect uncyclized Dha. DTT was dissolved in water at 1 M then aliquoted and stored at − 20 °C for up to two weeks. DTT solutions were added to the peptide solutions to give a final concentration of 250 mM, and pH was adjusted (if necessary) to 7.5. Reactions were conducted at 37 °C for 30 min before LC-MS analysis.
Preparation of duramycin and 11 (non-enzymatic reaction) in vitro.
Compound 3 was incubated with MBP-DurN (5:1, peptide: enzyme) in 100 mM Tris-HCl pH 7.5, 300 mM KCl, and 10 mM MgCl 2 at 37 °C for 12 h. No DTT addition to the peptide indicated full conversion of 3 . The reaction mixture was purified by analytical HPLC (see 'General methods'), and fractions containing 3 (judged by MS) were lyophilized. The dried peptide was dissolved in 50 mM Tris pH 8.5, then aminopeptidase was added at 0.1 U/μ g of peptide, and the reaction mixture was incubated at 37 °C for 12 h to remove the residual leader peptide residues. The reaction mixture was analyzed by analytical HPLC ('General methods'), MALDI-TOF-MS, LC-MS, and LC-MSMS indicating production of duramycin. For the preparation of 11 , compound 3 was incubated in 50 mM Tris-HCl pH 10 at 22-25 °C for 12 h, and the DTT assay indicated full consumption of 3 . Purification and removal of residual leader peptide residues to yield 11 was carried out as described above. Peptide concentrations were estimated by comparing the peak area at 214 nm in the LC chromatogram to that of authentic duramycin.
Activity assays for DurN and its mutants with 3 and its variants.
All assays were performed with 50 μ M modified DurA or its variants with 10 μ M or 5 μ M MBP-DurN or its mutants in 100 mM Tris-HCl pH 7.5, 300 mM KCl, and 50 mM MgCl 2. A positive control with MBP-DurN and compound 3 and a negative control with just MBP and compound 3 were included, as well as a negative control in which MBP-DurN (or its mutants) was omitted; control reactions were conducted in parallel to the reaction of interest under the same conditions. Reactions were incubated at 37 °C for 1 h and then treated with DTT using the procedure Crystallographic data collection, structure solutions, and refinement. Data were collected at the Advanced Photon Source at Argonne National Lab using the Life-Science Collaborative Access Team 21-ID-D, 21-ID-F, and 21-ID-G beamlines. Before collecting data, crystals were cryoprotected by immersing the crystals in similar solutions supplemented with 20% ethylene glycol and then flash-freezing in liquid nitrogen. To obtain phases experimentally, co-crystals of DurN and compound 6 were soaked with 0.5 M potassium iodide for 24 h at 16 °C and used to collect diffraction data at 8 keV. Data were initially processed using autoPROC 26 and further processed in autoSHARP to obtain phase information. The initial model was rebuilt using Buccaneer 27 and refined using REFMAC5 (ref. 28 ) in the CCP4 Software Suite. Diffraction data sets corresponding to apo-DurN crystals and DurN-duramycin co-crystals were phased after similar processing in autoPROC followed by molecular replacement using Phaser MR 29 . Ligand parameters for compound 6 and duramycin were determined using Phenix eLBOW 30 and modeled into their corresponding electron densities, followed by iterative rounds of automated REFMAC5 refinement and manual rebuilding in Coot 31 . Solvent molecules and potassium ions were first incorporated using Phenix Refine 32 or REFMAC5 then manually curated in Coot.
Differential scanning fluorimetry (DSF).
Tag-free DurN purified by SEC was solvent exchanged into a buffer lacking potassium or magnesium ions by subjecting to additional SEC on a 30 mL Superdex 200 10/300 GL column (GE Healthcare) equilibrated with 0.25 M NaCl and 20 mM HEPES pH 7.5. Protein was eluted using a similar running buffer, and pooled fractions were concentrated to 1 mg/mL. SYPRO orange dye was added to the protein at 8× final concentration and incubated at r.t. for 20 min. High-Profile 96-Well Semi-Skirted PCR plates (Bio-Rad Laboratories, Inc.) were used to serially titrate either KCl or MgCl 2 into the protein-dye mixture from 300 mM to 150 µ M or 200 mM to 100 µ M, respectively, and incubated for 25 min at 22-25 °C. Melting curves were obtained using a CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.) for which the sample was initially held at 25 °C for 3 min and then incrementally ramped to 98 °C at 0.5 °C every 10 s with plate-reading steps at every increment. The channel was set to "FRET" to satisfy the excitation and emission wavelengths of the SYPRO orange dye (λ ex 470 nm /λ em 570 nm). Data corresponding to the melt curves and first derivatives of the melt curves were obtained in the Bio-Rad CFX Manager 3.1 Data Analysis tool and subsequently plotted in OriginPro 2016 (OriginLab).
Mutational studies of DurN.
A number of residues make hydrophobic contacts at the dimeric interface (i.e., Leu22, Val24, Leu25, Leu28, Leu39, Leu43, Leu51, Ile54, Trp68, Leu72, Trp73, Leu85, Ile111, and Leu113). Additional electrostatic interactions are observed intermolecularly between Asp12-Lys103 and Arg18-Glu106, as well as intramolecularly between Lys34-Glu37 and Arg53-Glu82. Several MBP-tagged and site-directed DurN variants were constructed based on the co-crystal structures and sequence conservation between DurN homologs ( Supplementary Fig. 12 ). Specifically, Ala substitutions were generated at Arg17, Arg18, Gln20, Cys26, Lys66, Trp68, Ser79, Gln89, and Glu101 in addition to a Lys substitution at Arg17, and an end-point substrate conversion assay using compound 3 was performed (see Methods). Aside from DurN variants C26A and S79A, a diminution in activity relative to the wild-type DurN was observed for all DurN variants. These activity data are rationalized by the structural data, as residues Arg17, Gln20, and Lys66 are implicated in substrate binding, and residues Arg18, Trp68, and Glu101 are important for dimerization. Unsurprisingly, mutations at Cys26 and Ser79 exhibit no activity loss, as these residues are solvent exposed and distal to the ligand-binding site in the crystal structures.
Preparation and purification of Dur-FL. Duramycin (1 mg) was dissolved in 50 mM HEPES pH 7.5. Carboxyfluorescein succinimidyl ester (2 mg) was dissolved in 10 μ L of dimethyl sulfoxide and added to the reaction (total reaction volume = 1 mL). The reaction was left at 22-25 °C in the dark for 2 h, desalted and analyzed by MS, indicating both doubly and singly acylated duramycin. The products were purified by analytical HPLC (see 'General methods'), lyophilized, and stored at − 20 °C. Peptide concentration was estimated by comparing the peak area at 214 nm to that of duramycin and NHS-Fluorescence standard. Where y is polarization, A1 is the minimum polarization, A2 is the maximum polarization, X 0 is the IC 50 , p is the Hill coefficient, and x is the concentration of Dur-FL. A receptor depletion equation was also used to calculate the K d for comparison and did not yield a significant difference.
Competition fluorescence polarization (FP) binding studies. The same procedures were applied for all competition FP studies unless specified otherwise. The inhibitor of interest was prepared at 200 μ M in water and serially diluted 1:1 with FP buffer (300 mM KCl, 20 mM HEPES, pH 7.5) to provide 16 wells with concentrations ranging from 100 µ M to 0.003 µ M in a 96-well PCR plate. A solution of MBP-DurN (2 µ M) and Dur-FL (20 nM) was prepared in the same FP buffer and incubated at r.t. for 5 min before transferring 45 µ L to each well, then 80 μ L of the mixtures in each well were transferred to a black-bottomed 384-well plate (i.e., 80 μ L wells containing 1 μ M MBP-DurN, 10 nM Dur-FL, and inhibitor concentration ranging from 100 μ M to 3 nM). IC 50 values were calculated from the 50% saturation point using a dose-response curve fit in Origin Pro 9.1 (OriginLab) with three independent titrations. All IC 50 values were transferred to K i values by applying the Munson-Rodbard equation (see equation below) 33 .
Where y o is the initial bound to free ratio for the labeled species before perturbation of equilibrium by the added inhibitor, and L T is the total amount of labeled species.
Derivatization of lysinoalanine (Lal) standard. MeOD-d 4 (3 mL) was cooled in a 50 mL pear-shaped glass flask immersed in an ice-water bath. Acetyl chloride (0.9 mL) was added dropwise. This solution was added to 2 mg Lal standard (ll-and dl-lysinoalanine mixture, Bachem), and the reaction mixture was heated at 110 °C for 1 h under reflux then allowed to cool down to r.t. in air. The solvent was removed by a stream of nitrogen gas. Dichloromethane (3 mL) and pentafluoropropionic anhydride (1 mL) were added to the flask cooled in an icewater bath. The mixture was heated at 110 °C under reflux for 30 min and allowed to cool to r.t. and the solvent was removed under a stream of nitrogen gas for 2 h. For each sample, 800 μ L of pyridine was used to dissolve all resulting compounds, and the solutions were directly analyzed by GC-MS.
Hydrolysis and derivatization of duramycin, compound 11 , and deoxyduramycin.
The same hydrolysis and derivatization procedures were applied for all Lal-containing samples. To 1 mg of peptide, 3 mL of 6 M deuterium chloride in D 2 O was added to the sample (~1 mg) in a glass pressure tube (Ace Glass). The reaction mixture was heated without stirring at 80 °C for 4 h. The solution was transferred to a 50 mL pearshaped bottle, and the solvent was removed with a rotary evaporator. Then the same derivatizing procedures were used as described for the derivatization of Lal standard.
GC-MS analysis of lysinoalanine standard, duramycin, compound 11 , and deoxyduramycin. The derivatized samples were analyzed by GC-MS using an Agilent 7890 gas chromatograph equipped with a ZB-1MS column (Phenomenex, 30 m × 0.25 mm × 0.25 μ m). Samples were dissolved in 300 μ L of pyridine and a small volume was introduced to the instrument via a splitless injection at a flow rate of 1.6 mL/min helium gas. The front inlet was set to 230 °C for initial temperature, the purge flow was 20 mL/min, the purge time was 1 min, and the total flow was 24 mL/ min. The flow rate in the column was 1.6 mL/min. The temperature method used for the oven was 100 °C for 2 min, followed by 100 °C to 215 °C at 2. Structure preparation for computational studies. The crystallographic coordinates of duramycin bound to DurN homodimer were used to generate the starting structures for the simulations. The 11 unresolved resides at both N termini (MKSAKEPTTIYQ) were modeled as random coils in some simulations; the presence or absence of this highly flexible region did not have a significant impact in the observed results. Different crystallographic ions (K + and Mg 2+ ) were tested in the simulations, the best results being obtained with K + . The uncyclized duramycin precursor was modeled from co-crystallized duramycin by simply breaking the C β (Dha6)-N(Lys19) bond, slightly separating the fragments and minimizing the resulting structure with molecular mechanics using the appropriate generated parameters. When necessary mutations such as Hya15Asp in duramycin were introduced manually using PyMOL 1.8 (PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC).
MD simulations.
Unconstrained MD simulations in water were performed using the GPU accelerated code (pmemd) [34] [35] [36] of the Amber 16 and AmberTools 17 package 37 . Parameters for non-natural dehydro amino acids, (methyl)lanthionine, hydroxylated aspartic acid (Hya) and lysinoalanine (Lal) were generated within the antechamber module using the upgraded version of the general Amber force field (gaff2) 37 , with partial charges set to fit the electrostatic potential generated at the HF/6-31 G(d) level by the RESP (restrained electrostatic potential) model 38 .
The charges were calculated according to the Merz-Singh-Kollman scheme 39, 40 using the Gaussian 16 package 41 . Each peptide was immersed in a pre-equilibrated cubic box with a 10 Å buffer of TIP3P water molecules using the leap module, resulting in the addition of around 15,000 solvent molecules. The systems were neutralized by addition of explicit counter ions (K + and Cl -). All subsequent calculations were done using an evolved version of the Stony Brook modification of the Amber 99 force field (ff14SB) 42 . A two-stage geometry optimization approach was performed. The first stage minimizes the positions of solvent molecules and ions imposing positional restraints on solute by a harmonic potential with a force constant of 500 kcal mol −1 Å −2 , and the second stage was a minimization of all the atoms in the simulation cell. The systems were gently heated under periodicboundary conditions at a constant pressure of 1 atm. Water molecules were treated with the SHAKE algorithm such that the angle between the hydrogen atoms was kept fixed. Long-range electrostatic effects were modeled using the particle mesh Ewald method 43 . An 8 Å cutoff was applied to Lennard-Jones and electrostatic interactions. Harmonic restraints of 10 kcal/mol were applied to the solute, and the Andersen equilibration scheme was used to control and equalize the temperature. The time step was kept at 1 fs during the heating stage, allowing potential inhomogeneities to self-adjust for 100 ps. Each system was then equilibrated for 2 ns with a 2 fs time step at a constant volume and temperature of 300 K. Production trajectories were run for 1.0 μ s under the same conditions. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
Fluorescence polarization data were collected on Gen5 1.10.8. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry data were collected on Bruker Daltonics Compass 1.4 for flexSeries. Liquid chromatography-mass spectrometry data were collected on MassLynx V4.1 SCN639. Differential Scanning Fluorimetry data were collected with Bio-Rad CFX Manager 3.1. Size-exclusion chromatograms were collected and analyzed using PrimeView and PrimeView Evaluation. X-ray diffraction data were collected using software developed by the staff at LS-CAT (https://ls-cat.org/index.html) . MD simulations were carried out using GPU accelerated code (pmemd) of the Amber 16 and AmberTools 17 package using the Gaussian 16 package for charge calculations. Melting curves were obtained using a CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.).
Data analysis
Fluorescence polarization data were analyzed by OriginPro 2017. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry data were analyzed by Bruker Daltonics Compass 1.4 for flexSeries. Liquid chromatography-mass spectrometry data were analyzed on MassLynx V4.1 SCN639. X-ray diffraction data were processed using autoPROC, XDS, autoSHARP, Buccaneer, REFMAC5, CCP4, Phaser MR, eLBOW, Phenix Refine, and Coot. Modeling and figure generation was performed using PyMOL 1.8 and Chimera 1.10.2. Bio-Rad CFX Manager 3.1 Data Analysis tool was used to analyze DSF melt curves and the data plotted in OriginPro 2016 (OriginLab). All software packages and code used are commercially available or available in the literature. Gaussian 16 was used for the Quantum Mechanical calculations (RESP partial charges and structure minimization).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
